12 jul: Commonwealth Bank Australia To Cut Fixed Home Loan Rates To 3-Yea..
12 jul: EU To Market Test Reuters Code Commitments
12-07-2012 09:37:00

Actelion Launches First Job Cuts

Relateret indhold
Relateret debat
18 nov - 
If you find yourself able to discover the perfect gener..
18 nov - 
Novartis International AG / Nine new analyses show Nova..

By John Revill

ZURICH--Actelion Ltd. (ATLN.VX) will cut its workforce by up to 5% as part of its new cost-cutting program, as Europe's biggest biotechnology company by sales wrestles with the strong Swiss franc and the tough European market.

The cuts will be the first at Actelion since it was founded in 1997.

The company, based in Allschwil, Switzerland, Thursday said it could reduce up to 135 positions from its 2,500-strong workforce by the end of 2012, but didn't say how much it hopes to save from the cuts.

"In order to take full advantage of the growth opportunities ahead of us, we must take decisive action now," said Chief Executive Jean-Paul Clozel.

Around 70 jobs, mostly in R&D and general administration, are likely go at the Allschwil site in Switzerland, where 1,100 employees are currently based. Another 45 currently vacant positions won't be filled, Actelion said.

Pharmaceutical companies have recently been forced to act on steep drug price cuts in Europe and the U.S. and declining revenues as patents on key drugs expire.

Last month, Swiss pharmaceutical company Roche Holding AG (ROG.VX) said it would close a research-and-development site in Nutley, N.J., while Novartis AG (NVS) said in January it needs to save between $1.5 billion and $2.5 billion this year to stay on track.

Actelion, founded by two former Roche scientists, has been dealt a string of product setbacks, and is now banking on a new lung and heart drug called macitentan to become its new blockbuster product.

The company announced that it would be embarking on a cost-saving program in May. At the time, it said earnings wouldn't grow again until 2014 as new medicines and cost cuts would take time to offset falling sales of key pulmonary hypertension drug Tracleer.

Actelion has previously forecast flat core earnings for 2012 as it prepares for declines in sales of Tracleer, which accounts for around 90% of company sales but goes off patent in 2015.

In the first three months of 2012, the company reported a 16% decline in core earnings in Swiss francs--almost double the 9% fall in local currencies--as the currency traded at high levels against the dollar and the euro.

Actelion also Thursday said it is refocusing its R&D efforts toward rare diseases and specialty indications to generate more specialty franchises.

At 0704 GMT, Actelion shares were down CHF0.31, or 0.8%, at CHF40.56.

Write to John Revill at john.revill@dowjones.com

(END) Dow Jones Newswires

July 12, 2012 03:37 ET (07:37 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Aktier/tendens: Forsat prisfald for olien sender Mærsk i fokus

28-11-2014 08:26:24
Det danske aktiemarked ventes fredag at lægge roligt ud, efter at C20 Cap-indekset torsdag i handlens døende minutter vendte på en tallerken og endte dagen med ..

Roblon opjusterer resultatforventningerne til helåret - NY

27-11-2014 15:45:05
Efter at være blevet forelagt de foreløbige regnskabstal for regnskabsåret 2013/14 har bestyrelsen i Roblon fundet anledning til at justere på forventningerne t..

Jyske Bank sætter F1-rente på 0,3 pct.

27-11-2014 14:24:03
Jyske Bank har fastsat basisrenten på sit populære F1-banklån på 0,3 pct. Det sker, efter at renten på det klassiske F1-realkreditlån er landet på 0,51 pct. ved..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
SAS har succes med luksus-rute til USA - avis
2
Mærsk/Berenberg: Alt for billig - potentiale på cirka 50 pct
3
Aktier/middag: Investorerne skifter mening om Royal Unibrew
4
Lundbeck: Analytikerne skærer halvanden mia. af forventningerne
5
USA: Amerikansk aktiemarked lukket på grund af Thanksgiving

Relaterede aktiekurser

Novartis N 93,10 0,1% Stigning i aktiekurs
Roche GS 290,60 0,2% Stigning i aktiekurs
Actelion N 114,40 0,1% Stigning i aktiekurs
Roche I 284,25 -0,2% Fald i aktiekurs
Novartis AG Basel 95,56 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen
Køb

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
28. november 2014 09:27:38
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141127.2 - EUROWEB1 - 2014-11-28 09:27:38 - 2014-11-28 09:27:38 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x